StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.66+0.06 (+3.75%)

Close on Nov 17, 2026Market cap $4.22MP/E –Yield –

Alaunos Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Alaunos Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -135266.7%. For fiscal 2025 it was -84500.0%, against -48120.0% the year before. The highest annual figure on record is -336.4% in fiscal 2017.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-84500.0%−36380.0
FY2024Dec 31, 2024-48120.0%+637220.0
FY2023Dec 31, 2023-685340.0%−684138.6
FY2022Dec 31, 2022-1201.4%+18283.3
FY2021Dec 31, 2021-19484.7%+17437.2
FY2018Dec 31, 2018-36921.9%−36585.5
FY2017Dec 31, 2017-336.4%+2072.9
FY2016Dec 31, 2016-2409.4%+10361.8
FY2012Dec 31, 2012-12771.1%−2066.5
FY2011Dec 31, 2011-10704.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-30233.3%+143966.7
Q1 FY2025Mar 31, 2025-54600.0%+740300.0
Q4 FY2024Dec 31, 2024-18875.0%+180675.0
Q2 FY2024Jun 30, 2024-29150.0%+48313.6
Q1 FY2024Mar 31, 2024-174200.0%−173916.1
Q4 FY2023Dec 31, 2023-794900.0%−783806.8
Q2 FY2023Jun 30, 2023-199550.0%−198708.7
Q4 FY2022Dec 31, 2022-77463.6%−76645.2
Q3 FY2022Sep 30, 2022-283.9%+531.0
Q1 FY2018Mar 31, 2018-11093.2%−10218.7
Q4 FY2017Dec 31, 2017-841.3%–
Q3 FY2017Sep 30, 2017-818.4%–
Q2 FY2017Jun 30, 2017-814.9%–
Q1 FY2017Mar 31, 2017-874.5%–

More Alaunos Therapeutics figures

See a number that looks wrong?